Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-
care systems. Improving metabolic control to approach normal glycaemia (where practical) …

The concept of a “polypill” is receiving growing attention to prevent cardiovascular disease.
Yet similar if not overall higher benefits are achievable with regular exercise, a drug-free …

Abstract Type 2 diabetes (T2DM) is one of the most serious global health problems and is
mainly a result of the drastic increase in East Asia, which includes over a fourth of the global …

Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1)
are the two primary incretin hormones secreted from the intestine on ingestion of various …

The discovery of incretin-based medications represents a major therapeutic advance in the
pharmacological management of type 2 diabetes mellitus (T2DM), as these agents avoid …

Aims To compare the HbA1c‐lowering efficacy of glucagon‐like peptide‐1 (GLP‐1)
analogues between Asians and non‐Asians with type 2 diabetes. Methods We searched …

Introduction: Dipeptidyl peptidase (DPP)-4 inhibitors belong to one class of drugs that have
been approved for treatment of type 2 diabetes (T2D) based on the glucose-lowering actions …

Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) occupy an increasing place
in the armamentarium of drugs used for the management of hyperglycaemia and offer new …

Gastrointestinal hormones are currently used to treat type 2 diabetes mellitus (T2D). Incretin
preparations with gastric inhibitory polypeptide (GIP) activity or glucagon-like peptide-1 …

Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are oral incretin-based glucose-
lowering agents with proven efficacy and safety in the management of type 2 diabetes …